Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. (Q55462450)

12 July 2018

title

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. (English)

1 reference

12 July 2018

0 references

Akitake Mukasa

1

1 reference

12 July 2018

Shunsaku Takayanagi

2

1 reference

12 July 2018

Kuniaki Saito

3

1 reference

12 July 2018

Junji Shibahara

4

1 reference

12 July 2018

Yusuke Tabei

5

1 reference

12 July 2018

Kazuhide Furuya

6

1 reference

12 July 2018

Takafumi Ide

7

1 reference

12 July 2018

Yoshitaka Narita

8

1 reference

12 July 2018

Ryo Nishikawa

9

1 reference

12 July 2018

Keisuke Ueki

10

1 reference

12 July 2018

Nobuhito Saito

11

1 reference

12 July 2018

publication date

13 January 2012

1 reference

12 July 2018

published in

Cancer Science

1 reference

12 July 2018

volume

103

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

587-592

1 reference

12 July 2018

An integrated genomic analysis of human glioblastoma multiforme

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Molecular Classification of Low-Grade Diffuse Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02175.X

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

21 January 2018

1 reference

12 December 2020

Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas

1 reference

12 December 2020

IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas

1 reference

12 December 2020

Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.

1 reference

12 December 2020

10.1111/J.1349-7006.2011.02175.X

Identifiers

DOI

1 reference

12 July 2018

1 reference

12 July 2018